- Email: [email protected]
Correction to Lancet Haematol 2015; 2: e364
Corrections
Correction to Lancet Haematol 2015; 2: e364
Correction to Lancet Haematol 2015; 2: e498
Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol 2015; 2: e357–66— In table 5, the p value for APML4 vs APML3 for overall survival in high-risk patients should have been 0·40, not 0·040. This correction has been made to the online version as of Nov 5, 2015.
Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol 2015; 2: e492–502— In this Article, scale of the graph in figure 2B has been corrected. This correction has been made to the online version as of Nov 5, 2015.
www.thelancet.com/haematology Vol 2 November 2015
e464
Correction to Lancet Haematol 2015; 2: e364
Correction to Lancet Haematol 2015; 2: e498
Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol 2015; 2: e357–66— In table 5, the p value for APML4 vs APML3 for overall survival in high-risk patients should have been 0·40, not 0·040. This correction has been made to the online version as of Nov 5, 2015.
Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol 2015; 2: e492–502— In this Article, scale of the graph in figure 2B has been corrected. This correction has been made to the online version as of Nov 5, 2015.
www.thelancet.com/haematology Vol 2 November 2015
e464